Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions. It offers its products through wholesale drug distributors, and stockiest and retail pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for ERIS
Revenue projections for ERIS

With ERIS's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 0.000000
forwardPE 26.586468
debtToEquity 68.185000
earningsGrowth 0.191000
revenueGrowth 0.109000
grossMargins 0.739070
operatingMargins 0.263790
trailingEps 31.550000
forwardEps 50.491850

ERIS's Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
ERIS's positive earnings and revenue growth indicate that the company is expected to continue expanding its business. These trends reflect strong financial health, with increasing profits and sales suggesting sustained growth and success for ERIS.
With positive gross and operating margins, Eris Lifesciences Limited's profitability is evident. These metrics suggest the company is efficiently managing its expenses while maintaining strong revenue, highlighting a solid financial foundation.
ERIS's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting ERIS to generate stronger earnings compared to the previous financial year.

Price projections:

Price projections for ERIS
Price projections for ERIS

ERIS's current valuation aligns with projections, revealing no significant risks or opportunities. This stable environment may lead investors to adopt a wait-and-see strategy, monitoring future developments closely.

Recommendation changes over time:

Recommendations trend for ERIS
Recommendations trend for ERIS


Analysts are favoring ERIS with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider ERIS as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.